Reset
Page 1 of 1 Pages
Posts Per Page
Jordan Smith commented 1 month ago
#25088

Roots Analysis has done a detailed study on Large Volume Wearable Injectors Market (5th Edition), 2020-2030: Focus on Bolus, Basal and Continuous Delivery Devices, covering key aspects of the industry’s current trends and identifying potential future growth opportunities.

 

To order this 540+ page report, which features 175+ figures and 200+ tables, please visit this link

 

Key Market Insights

  • More than 40 large volume wearable injectors are presently available / under development for the administration of drugs, beyond insulin, including 15+ drug device combinations
  • Companies focused on developing devices for the delivery of insulin have already established strong brand positions in this domain, with 30+ devices currently under development or available
  • More than 200 biologics / small molecule drugs were identified as likely products to be developed in combination with large volume wearable injectors
  • The rising interest in this field is reflected in the number of partnerships (90+) inked between 2015

and 2020 (till June), involving both international and indigenous stakeholders, across the world

  • An evaluation of 50+ stakeholders engaged in the development of large volume wearable injectors revealed the existence of several likely acquisition targets, across different geographical regions
  • The market, for the large volume wearable injectors for the delivery of non-insulin drugs  is projected to be worth USD 600 million; owing to the increasing incidence of chronic clinical conditions and growing pipeline of therapeutic interventions to treat such diseases
  • The large volume wearable injectors market for insulin is anticipated to be worth over USD 2.7 billion by 2030; the anticipated opportunity is likely to be distributed across various different device types, therapeutic areas and geographies

 

For more information, please visit https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors-market-4th-edition-2018-2030/238.html

                                                                                                               

Table of Contents

 

1.         PREFACE

1.1.      Scope of the Report

1.2.      Research Methodology

1.3.      Chapter Outlines

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

3.1.      Chapter Overview

3.2.      An Overview of Drug Delivery Devices

3.3.      Conventional Parenteral Drug Delivery

3.3.1     Needlestick Injuries

 

3.4.      Emergence of Self-Administration Devices

3.4.1.    Driving Factors

 

3.5.      Available Self-Injection Devices

3.5.1.    Prefilled Syringes

3.5.2.    Pen-Injectors

3.5.3.    Needle-Free Injectors

3.5.4.    Autoinjectors

3.5.5.    Large Volume Wearable Injectors

 

3.6.      Regulatory Considerations

3.6.1.    Medical Devices

3.6.2.    Drug Device Combination Products

 

3.7.      Future Perspectives of Self-Injection Systems

 

4.         LARGE VOLUME WEARABLE INJECTORS: CURRENT MARKET LANDSCAPE

4.1.      Chapter Overview

4.2.      Large Volume Wearable Injectors: Overall Market Landscape

4.2.1.    Large Volume Wearable Injectors for Non-Insulin Drugs: Market Landscape

4.2.1.1. Analysis by Stage of Development

4.2.1.2. Analysis by Type of Device

4.2.1.3. Analysis by Type of Dose

4.2.1.4. Analysis by Route of Administration

4.2.1.5. Analysis by Mode of Injection

4.2.1.6. Analysis by Volume / Storage Capacity

4.2.1.7. Analysis by Actuation Mechanism

4.2.1.8. Analysis by Usability

4.2.1.9. Analysis by Availability of Prefilled Drug Reservoir

4.2.1.10. Analysis by Availability of Connectivity

 

4.2.2.    Large Volume Drug Device Combinations: Market Landscape

4.2.2.1. Analysis by Stage of Development

4.2.2.2. Analysis by Type of Device

4.2.2.3. Analysis by Drug Compatibility

4.2.2.4. Analysis by Type of Dose

4.2.2.5. Analysis by Route of Administration

4.2.2.6. Analysis by Mode of Injection

4.2.2.7. Analysis by Therapeutic Area

4.2.2.8. Analysis by Volume / Storage Capacity

4.2.2.9. Analysis by Usability

 

4.2.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Analysis of Developers (Devices    and Drug Device Combinations)

4.2.3.1. Analysis by Year of Establishment

4.2.3.2. Analysis by Company Size

4.2.3.3. Analysis by Geography

 

4.2.4.    Large Volume Wearable Injectors for Insulin: Market Landscape

4.2.4.1. Analysis by Stage of Development

4.2.4.2. Analysis by Type of Device

4.2.4.3. Analysis by Volume / Storage Capacity

4.2.4.4. Analysis by Usability

4.2.4.5. Analysis by Availability of Prefilled Insulin Cartridges

4.2.4.6. Analysis by Availability of CGM / BGM System

4.2.4.7. Analysis by Availability of Automated Insulin Delivery (AID) Feature

4.2.4.8. Analysis by Availability of Connectivity

4.2.4.9. Analysis by Type of Remote Control Features

 

4.2.5.    Large Volume Wearable Injectors for Insulin: Analysis of Developers

4.2.5.1. Analysis by Year of Establishment

4.2.5.2. Analysis by Company Size

4.2.5.3. Analysis by Geography

 

5.         PRODUCT COMPETITIVENESS ANALYSIS

5.1.      Chapter Overview

5.2.      Methodology

5.3.      Assumptions / Key Parameters

5.4.      Product Competitiveness Analysis

5.4.1.    Large Volume Wearable Injectors for Non-Insulin Drugs

5.4.2.    Large Volume Drug Device Combinations

5.4.3.    Large Volume Wearable Injectors for Insulin

 

6.         LARGE VOLUME WEARABLE INJECTORS: KEY PLAYERS

6.1.      Chapter Overview

6.2.      Large Volume Wearable Injectors for Non-Insulin Drugs: Key Players

6.2.1.    Becton Dickinson

6.2.1.1. Company Snapshot

6.2.1.2. Financial Information

6.2.1.3. Product Portfolio

6.2.1.4. Recent Developments and Future Outlook

6.2.2.    Bespak

6.2.2.1. Company Snapshot

6.2.2.2. Financial Information

6.2.2.3. Product Portfolio

6.2.2.4. Recent Developments and Future Outlook

 

6.2.3.    Enable Injections

6.2.3.1. Company Snapshot

6.2.3.2. Product Portfolio

6.2.3.3. Recent Developments and Future Outlook

 

6.2.4.    Insulet

6.2.4.1. Company Snapshot

6.2.4.2. Financial Information

6.2.4.3. Product Portfolio

6.2.4.4. Recent Developments and Future Outlook

 

6.2.5.    Roche

6.2.5.1. Company Snapshot

6.2.5.2. Financial Information

6.2.5.3. Product Portfolio

6.2.5.4. Recent Developments and Future Outlook

 

6.2.6.    Sensile Medical

6.2.6.1. Company Snapshot

6.2.6.2. Product Portfolio

6.2.6.3. Recent Developments and Future Outlook

 

6.2.7.    Sonceboz

6.2.7.1. Company Snapshot

6.2.7.2. Product Portfolio

6.2.7.3. Recent Developments and Future Outlook

 

6.2.8.    SteadyMed Therapeutics

6.2.8.1. Company Snapshot

6.2.8.2. Product Portfolio

6.2.8.3. Recent Developments and Future Outlook

 

6.2.9.    Weibel CDS    

6.2.9.1. Company Snapshot

6.2.9.2. Product Portfolio

6.2.9.3. Recent Developments and Future Outlook

 

6.2.10.  West Pharmaceutical Services           

6.2.10.1. Company Snapshot

6.2.10.2. Financial Information

6.2.10.3. Product Portfolio

6.2.10.4. Recent Developments and Future Outlook

 

6.3.      Large Volume Wearable Injectors for Insulin: Key Players

 

6.3.1.    CeQur

6.3.1.1. Company Snapshot

6.3.1.2. Product Portfolio

6.3.1.3. Recent Developments and Future Outlook

 

6.3.2.    Debiotech

6.3.2.1. Company Snapshot

6.3.2.2. Product Portfolio

6.3.2.3. Recent Developments and Future Outlook

 

6.3.3.    Eli Lilly

6.3.3.1. Company Snapshot

6.3.3.2. Financial Information

6.3.3.3. Product Portfolio

6.3.3.4. Recent Developments and Future Outlook

 

6.3.4.    Medtronic

6.3.4.1. Company Snapshot

6.3.4.2. Financial Information

6.3.4.3. Product Portfolio

6.3.4.4. Recent Developments and Future Outlook

 

6.3.5.    PharmaSens

6.3.5.1. Company Snapshot

6.3.5.2. Product Portfolio

6.3.5.3. Recent Developments and Future Outlook

 

6.3.6.    SOOIL Development

6.3.6.1. Company Snapshot

6.3.6.2. Product Portfolio

6.3.6.3. Recent Developments and Future Outlook

 

6.3.7.    Tandem Diabetes Care

6.3.7.1. Company Snapshot

6.3.7.2. Financial Information

6.3.7.3. Product Portfolio

6.3.7.4. Recent Developments and Future Outlook

           

 

7.       DRUG-DEVICE COMBINATIONS: TABULATED PROFILES

7.1.    Chapter Overview

7.2.    Apomorphine / D-mine® Pump

7.3.    Apomorphine / ND0701

7.4.    Bupivacaine / SMT-301

7.5.    Ceftriaxone / sc2Wear® Infusor

7.6.    Furosemide / 3 mL Micropump

7.7.    Furosemide / FUROSCIX® On-body Infusor

7.8.    Herceptin® / Single Use Injector

7.9.    Ketorolac / SMT-201

7.10.  Levodopa and Carbidopa / ND0612 and ND0901

7.11.  Lutrepulse / The LUTREPULSE® System

7.12.  Neulasta® / Neulasta OnPro™ On-body Injector

7.13.  Repatha® / Pushtronex® System

7.14.  Treprostinil / Trevyent®

 

8.         PARTNERSHIPS AND COLLABORATIONS

8.1.      Chapter Overview

8.2.      Partnership Models

8.3.      Large Volume Wearable Injectors: List of Partnerships and Collaborations

8.3.1.    Analysis by Year of Partnership

8.3.2.    Analysis by Type of Partnership

8.3.3.    Analysis by Type of Device

8.3.4.    Analysis by Year of Partnership and Type of Partner

8.3.5.    Most Active Players: Analysis by Number of Partnerships

8.3.6.    Regional Analysis

8.3.7.    Intercontinental and Intracontinental Agreements

 

9.         KEY ACQUISITION TARGETS

9.1.      Chapter Overview

9.2.      Scope and Methodology

9.3.      Scoring Criteria and Key Assumptions

9.4.      Potential Strategic Acquisition Targets for Non-Insulin Drug Delivery Players

9.5.      Potential Strategic Acquisition Targets for Insulin Drug Delivery Players

9.6.      Concluding Remarks

           

10.       PATENT ANALYSIS

10.1.     Chapter Overview

10.2.     Scope and Methodology

10.3.     Large Volume Wearable Injectors: Patent Analysis

10.3.1.  Analysis by Publication Year

10.3.2.  Analysis by Issuing Authority / Patent Offices Involved

10.3.3.  Analysis by CPC Symbols

10.3.4.  Emerging Focus Areas

10.3.5.  Analysis by Type of Organization

10.3.6.  Leading Players: Analysis by Number of Patents

 

10.4.     Large Volume Wearable Injectors: Patent Benchmarking Analysis

10.4.1.  Analysis by Patent Characteristics

 

10.5.     Large Volume Wearable Injectors: Patent Valuation Analysis

 

11.       LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

11.1.     Chapter Overview

11.2.     Marketed Drugs          

11.2.1.  Most Likely Candidates for Delivery via Large Volume Wearable Injectors

11.2.2.  Likely Candidates for Delivery via Large Volume Wearable Injectors

11.2.3.  Less Likely Candidates for Delivery via Large Volume Wearable Injectors

11.2.4.  Unlikely Candidates for Delivery via Large Volume Wearable Injectors

 

11.3.     Clinical Drug Candidates

11.3.1.  Biologics

11.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.1.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

 

11.3.2.    Small Molecules

11.3.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors

11.3.2.4. Unlikely Candidates for Delivery via Large Volume Wearable Injectors

 

12.       EMERGING TRENDS ON SOCIAL MEDIA

12.1.     Chapter Overview

12.2.     Large Volume Wearable Injectors: Trends on Twitter

12.2.1.  Historical Trend in Volume of Tweets

12.2.2.  Trending Words / Phrases Related to Large Volume Wearable Injectors

12.2.3.  Most Influential Authors

 

12.2.4.  Popular Players on Twitter

12.2.4.1.    Roche (ACCU-CHEK® Solo Micropump System)

12.2.4.2.    Insulet (Omnipod®)

12.2.4.3.    Medtronic (MiniMed® Wearable Injectors)

12.2.4.4.    Comparison of Popular Players Based on Number of Tweets

12.3.     Concluding Remarks

 

13.       CLINICAL TRIAL ANALYSIS

13.1.     Chapter Overview

13.2.     Scope and Methodology

13.3.     Large Volume Wearable Injectors: Clinical Trial Analysis

13.3.1.  Analysis by Trial Registration Year

13.3.2.  Analysis by Trial Phase

13.3.3.  Analysis by Trial Recruitment Status

13.3.4.  Analysis by Trial Registration and Number of Patients Enrolled

13.3.5.  Analysis by Study Design

13.3.6.  Analysis by Type of Sponsor / Collaborator

13.3.7.  Leading Players: Analysis by Number of Registered Trials

13.3.8.  Word Cloud: Key Focus Areas

13.3.9.  Analysis by Therapeutic Area

13.3.10.  Popular Drug Device Combinations: Analysis by Number of Registered Trials

13.3.11.  Geographical Analysis by Number of Registered Trials

13.3.12.  Geographical Analysis by Patients Enrolled

13.3.13.  Analysis by Clinical Endpoints        

           

14.       CASE STUDY: ROLE OF CMOs IN DEVICE DEVELOPMENT SUPPLY CHAIN

14.1.     Chapter Overview

14.2.     Device Development Supply Chain

14.3.     Significance of CMOs in the Drug Delivery Device Development Process

14.4.     List of Contract Manufacturing Organizations

14.4.1.  Contract Manufacturers: Geographical Distribution and Services Offered

 

15.       REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

15.1.       Chapter Overview

15.2.       General Regulatory and Reimbursement Guidelines for Medical Devices

 

15.3.       Regulatory and Reimbursement Landscape in North America

15.3.1.    The US Scenario

15.3.2.     The Canadian Scenario

15.3.3.     The Mexican Scenario

 

15.4.       Regulatory and Reimbursement Landscape in Europe

15.4.1.    Overall Scenario

15.4.1.1. Overall Regulatory Authority

15.4.1.2. Overall Review / Approval Process

15.4.2.    The UK Scenario

15.4.3.    The French Scenario

15.4.4.    The German Scenario

15.4.5.    The Italian Scenario

15.4.6.    The Spanish Scenario

 

15.5.       Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World

15.5.1.    The Australian Scenario

15.5.2.    The Brazilian Scenario

15.5.3.    The Chinese Scenario

15.5.4.    The Indian Scenario

15.5.5.    The Israeli Scenario

15.5.6.    The Japanese Scenario

15.5.7.    The New Zealand Scenario

15.5.8.    The Singaporean Scenario

15.5.9.    The South Korea Scenario

15.5.10.  The South African Scenario

15.5.11.  The Taiwanese Scenario

15.5.12.  The Thailand Scenario

 

15.6.     Comparison of Regional Regulatory Environment

15.7.     Concluding Remarks

 

16.       MARKET SIZING AND OPPORTUNITY ANALYSIS

16.1.     Chapter Overview

16.2.     Forecast Methodology and Key Assumptions

16.3.     Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Value)

16.3.1.  Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Value)

16.3.2   Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Value)

16.3.3   Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Value)

 

16.4      Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Value)

16.4.1   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Value)

16.4.2   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Value)

16.4.3   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Value)

 

16.5      Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Value)

16.5.1   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Value)

16.5.2   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Value)

16.5.3   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Value)

 

16.6      Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)

16.6.1   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)

16.6.2   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

16.6.3   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)

 

16.7.     Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2020-2030 (By Volume)

16.7.1.  Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2020-2030 (By Volume)

16.7.2   Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2020-2030 (By Volume)

16.7.3   Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2020-2030 (By Volume)

 

16.8      Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2020-2030 (By Volume)

16.8.1   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2020-2030 (By Volume)

16.8.2   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2020-2030 (By Volume)

16.8.3   Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2020-2030 (By Volume)

 

16.9      Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2020-2030 (By Volume)

16.9.1   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2020-2030 (By Volume)

16.9.2   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2020-2030 (By Volume)

16.9.3   Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2020-2030 (By Volume)

 

16.10    Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2020-2030 (By Value)

16.10.1 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2020-2030 (By Value)

16.10.2 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2020-2030 (By Value)

16.10.3             Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2020-2030 (By Value)

 

16.11.   Global Large Volume Wearable Injectors Market for Insulin, 2020-2030

16.11.1 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2020-2030

16.11.2 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2020-2030

 

16.12    Large Volume Wearable Injectors Market for Insulin in North America, 2020-2030

16.12.1 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2020-2030

16.12.2 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2020-2030

 

16.13    Large Volume Wearable Injectors Market for Insulin in Europe, 2020-2030

16.13.1 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2020-2030

16.13.2 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2020-2030

 

16.14    Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2020-2030

16.14.1 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2020-2030

16.14.2 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2020-2030

 

17.       SWOT ANALYSIS

17.1.     Chapter Overview

17.2.     SWOT Analysis

17.2.1.  Strengths

17.2.2.  Weaknesses

17.2.3.  Opportunities

17.2.4.  Threats

 

17.3.     Large Volume Wearable Injectors: Future Growth Opportunities

17.3.1.  Rising Focus on Self-Administration of Drugs

17.3.2.  Possibility of Integration with Mobile Applications

17.3.3.  Potential Life Cycle Management Tool

17.3.4.  Potential Usability for Multiple Therapeutic Areas

 

18.       EXECUTIVE INSIGHTS

18.1.     Chapter Overview

 

18.2.     Subcuject

18.2.1.  Company Snapshot

18.2.2.  Interview Transcript: Jesper Roested, Chief Executive Officer (Q2 2020)

 

18.3.     Sorrel Medical

18.3.1.  Company Snapshot

18.3.2.  Interview Transcript: Mindy Katz, Director of Product (Q2 2020)

 

18.4.     Medipacs

18.4.1.  Company Snapshot

18.4.2.  Interview Transcript: Mark Banister, Chief Executive Officer (Q3 2016)

 

18.5.     Elcam Medical

18.5.1.  Company Snapshot

18.5.2.  Interview Transcript: Menachem Zucker, Vice President and Chief Scientist (Q3 2016)

 

18.6.     West Pharmaceutical Services

18.6.1.  Company Snapshot

18.6.2.  Interview Transcript: Graham Reynolds, Vice President and General Manager, Biologics (Q3 2016)

 

18.7.     Enable Injections

18.7.1.  Company Snapshot

18.7.2.  Interview Transcript: Michael Hooven, Chief Executive Officer (Q3 2014)

 

 

18.8.     scPharmaceuticals

18.8.1.  Company Snapshot

18.8.2.  Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer    (Q3 2014)

 

 

19.       APPENDIX 1: TABULATED DATA

 

20.       APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com


Information!  Use the form below to reply to this forum thread or, to reply to an individual post, use the "Quote" button on the relevant post.